Shanghai Shyndec Pharmaceutical Co Ltd600420
Mentioned
Impact on assets 1
Others
Shanghai Shyndec Pharmaceutical Co LtdTheme Impact 1
Off-coverage companies
Related news
United States▲4
NRx Pharma rises as FDA completes initial review of ketamine product
Shares of NRx Pharmaceuticals rose after the FDA completed an initial review of its marketing application for a preservative-free ketamine product without identifying any major drug-related deficiencies. The regulator did not require new clinical or drug-related findings to prove safety and efficacy, but it classified a question about the luer lock tip of the medication vial as a major deficiency. Following a clarification meeting on August 6, NRx Pharma cited a substantially de-risked path to approval, noting that three ANDA-approved products on the market use the same luer-lock vial. CEO Jonathan Javitt said the company is encouraged by the FDA's commitment to review the remaining information in the shortest possible cycle.
About megatrends
Psychedelic Medicine › Ketamine & Esketamine ▲Regulation
▲10impact 4
Eli Lilly to acquire AtaiBeckley for $2.8 billion
Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $2.8 billion. The deal, which could be valued at up to $3.8 billion, marks a significant move into psychedelic-based mental health treatments. Mizuho Americas healthcare equity strategist Jared Holz noted that large-cap pharma is increasingly embracing alternative therapies, citing J&J's ketamine-based product annualizing nearly $2 billion. Holz expects 2025 to be a historic year for biotech M&A, with over 30 transactions north of a billion dollars.
About megatrends
Psychedelic Medicine › Psilocybin Therapeutics ▲Capital
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Competition
Psychedelic Medicine › Ketamine & Esketamine ▲Competition
LLY · Capital · Positive Eli Lilly is the acquirer, expanding into psychedelic treatments via the $2.8B deal
ATAI · Capital · Positive ATAI Life Sciences is the target of the acquisition, providing a premium to shareholders
2
AtaiBeckley Joins Russell 2000 and 3000 Indices, Canaccord Raises Price Target to $17
AtaiBeckley N.V. will be added to the Russell 2000 and Russell 3000 indices effective June 29, a move the company notes is significant given over $12 trillion in assets benchmarked to Russell indexes. Canaccord Genuity subsequently raised its price target on the stock from $15 to $17 on July 7, implying more than 227% upside, while reiterating a Buy rating. The revision followed completion of dosing in the Phase 2 Elumina trial of VLS-01 for treatment-resistant depression, with the company targeting Phase 3 development for major depressive disorder and potential expansion into generalized anxiety disorder. AtaiBeckley is a clinical-stage biopharmaceutical company focused on mental health therapies, with a pipeline that includes BPL-003 in Phase 2 for treatment-resistant depression and alcohol addiction, and RL-007 for cognitive decline from schizophrenia.
About megatrends
Psychedelic Medicine › Psilocybin Therapeutics Capital
Psychedelic Medicine › Novel Psychedelic & Next-Gen Pipeline Capital
Psychedelic Medicine › Ketamine & Esketamine Capital
ATAI · Capital · Positive Index inclusion and analyst price target raise are positive financial events.
Three Psychedelic Stocks With Potential Clinical Trial Catalysts
Optimi Health, AtaiBeckley, and COMPASS Pathways are three psychedelic medicine companies with upcoming clinical trial catalysts that could reshape their risk-reward profiles. Optimi Health, a Canadian manufacturer with a Health Canada-licensed GMP facility, is already shipping pharmaceutical-grade MDMA and psilocybin into Australia's reimbursed prescription market, though its revenue remains below CA$1 million. AtaiBeckley has multiple Phase 2 programs targeting treatment-resistant depression and social anxiety, with Phase IIb data expected in 2026 and potential progression to Phase 3 trials, but it faces widening losses and high funding risk. COMPASS Pathways is advancing its psilocybin therapy COMP360 in Phase III for treatment-resistant depression and plans to file a rolling NDA with the FDA, yet it remains pre-revenue with a history of shareholder dilution.
About megatrends
Psychedelic Medicine › Psilocybin Therapeutics Regulation
Psychedelic Medicine › Novel Psychedelic & Next-Gen Pipeline Technology
Psychedelic Medicine › MDMA-Assisted Therapy Supply
Psychedelic Medicine › Ketamine & Esketamine Competition
OPTH · Demand · Positive Shipping pharmaceutical-grade MDMA and psilocybin into Australia's reimbursed prescription market
ATAI · Technology · Neutral Multiple Phase 2 programs with upcoming data, but faces widening losses and high funding risk